deaths (OS)

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus trastuzumab emtansine
trastuzumab deruxtecan vs. trastuzumab emtansine 1 0.55 [0.36; 0.85], 1 RCT, I2=0%
unassessable degree of certainty